- Home
- RNAZ vs SINT Comparison
RNAZ vs SINT Comparison
Compare RNAZ & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- SINT
- Stock Information
- Founded
- RNAZ 2016
- SINT 1996
- Country
- RNAZ United States
- SINT United States
- Employees
- RNAZ N/A
- SINT N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- SINT Medical/Dental Instruments
- Sector
- RNAZ Health Care
- SINT Health Care
- Exchange
- RNAZ Nasdaq
- SINT Nasdaq
- Market Cap
- RNAZ 4.9M
- SINT 4.6M
- IPO Year
- RNAZ 2021
- SINT 2014
- Fundamental
- Price
- RNAZ $3.35
- SINT $3.18
- Analyst Decision
- RNAZ Strong Buy
- SINT Hold
- Analyst Count
- RNAZ 1
- SINT 1
- Target Price
- RNAZ $20.00
- SINT N/A
- AVG Volume (30 Days)
- RNAZ 143.7K
- SINT 156.3K
- Earning Date
- RNAZ 11-14-2024
- SINT 11-12-2024
- Dividend Yield
- RNAZ N/A
- SINT N/A
- EPS Growth
- RNAZ N/A
- SINT N/A
- EPS
- RNAZ N/A
- SINT N/A
- Revenue
- RNAZ N/A
- SINT $3,247,000.00
- Revenue This Year
- RNAZ N/A
- SINT $15.42
- Revenue Next Year
- RNAZ N/A
- SINT $14.58
- P/E Ratio
- RNAZ N/A
- SINT N/A
- Revenue Growth
- RNAZ N/A
- SINT 30.40
- 52 Week Low
- RNAZ $2.66
- SINT $2.01
- 52 Week High
- RNAZ $66.33
- SINT $65.00
- Technical
- Relative Strength Index (RSI)
- RNAZ 30.32
- SINT 43.08
- Support Level
- RNAZ $2.90
- SINT $3.10
- Resistance Level
- RNAZ $3.50
- SINT $3.94
- Average True Range (ATR)
- RNAZ 0.42
- SINT 0.28
- MACD
- RNAZ 0.31
- SINT -0.06
- Stochastic Oscillator
- RNAZ 50.74
- SINT 8.00
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About SINT SiNtx Technologies Inc.
SINTX Technologies Inc is an advanced ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing primarily on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.